The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

NeoALTTO: European Journal of Cancer (EJC)

Jan 16, 2023

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

Overall survival in the OlympiA trial

Dec 1, 2022

OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo

APHINITY | Annals of Oncology

Sep 1, 2022

Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up

OlympiA | ESMO Virtual Plenary Abstract | Annals of Oncology

May 9, 2022

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

APHINITY | Journal of the National Cancer Institute (JNCI)

May 5, 2022

Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

APHINITY | AACR Cancer Research

Feb 15, 2022

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

The ALTTO Trial: Updated Results from the international phase III ALTTO trial (BIG2-06/Alliance N063D)

May 1, 2021

Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial as shown at the 2017 annual meeting of the American Society of Clinical Oncology and published in the European Journal of Cancer in 2021.

The APHINITY Trial: Results of the Interim Overall Survival Analysis at 6 years’ follow-up

May 1, 2021

The JCO confirms the invasive disease-free survival benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early breast cancer.

A pooled analysis of the Cardiac Events in three adjuvant trials: HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials)

Jan 1, 2020

Breast Cancer Research and Treatment published that Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Further research is needed to individualize prevention and management of trastuzumab-associated cardiotoxicity.